Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic range albuminuria.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2019003633
Abstract: Daratumumab has shown promising first results in systemic light-chain amyloidosis (AL). We analyzed a consecutive series of 168 patients with advanced AL receiving either daratumumab/dexamethasone (DD, n=106) or daratumumab/bortezomib/dexamethasone (DVD, n=62). DD achieved a remission… read more here.
Keywords: amyloidosis; rate; range albuminuria; daratumumab ... See more keywords
Baseline moderate-range albuminuria is associated with protection against severe COVID-19 pneumonia
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Diabetes"
DOI: 10.4239/wjd.v13.i12.1154
Abstract: BACKGROUND Diabetes mellitus is considered a leading contributor to severe coronavirus disease 2019 (COVID-19). AIM To characterize differences between hospitalized diabetic patients with vs without COVID-19, and parameters associated with COVID-19 severity for prediction. METHODS… read more here.
Keywords: covid pneumonia; range albuminuria; severe covid; covid ... See more keywords